The company has currently focus on areas where there are large unmet medical needs - like e.g. Hemophilia A where patients have developed antibodies against its vital treatment with factor VIII. Another example is patients that have received a kidney transplant and where they are of risk of developing a rejection.

The first clinical study within the IDO 8 program has, as previously announced, received regulatory approval in both Sweden and Norway. The first patient is planned to be included during the autumn.

The company's technology platform is scalable, which means that the toleragenic cells can be adapted to various types of antigens. This could widen the areas of use to other diseases where the patient's own immune system develops an undesired attack against tissue or transplanted organ.

"We are today very glad to announce EPB's initial coverage of our company. As a comment to the actual analysis, I would to mention that our Key Opinion Leaders see a potential that our cell therapy could be used earlier in the treatment paradigm and thus replace the rather difficult, conventional immunotolerabilization currently used with factor VIII (so called ITI). If this turns out to be the case, our target population could be three time larger than what EPB has estimated" says Christina Herder, acting CEO.

The initiation analysis can be found here  https://docs.penser.se/a/3032/IDOGEN20220831.pdf

For further information, please contact:

Christina Herder, Acting CEO, Idogen AB

Phone: +46 70374 71 56

Email: christina.herder@idogen.com

Certified Adviser:
The companies Certified Adviser is Vator Securities AB. Contact information: Vator Securities AB, Kungsgatan 34, SE-111 35 Stockholm, Email: ca@vatorsec.se.Tel: +46 (0)8-580 065 99

The information was submitted for publication, through the agency of the contact persons set out above, on 2 September 2022 at 09:16 CET.

The English text is an unofficial translation of the original Swedish text. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.

Idogen (Nasdaq First Growth Market: IDOGEN) develops tolerogenic cell therapies to prevent the patient's immune system from attacking biological agents, transplanted organs or the body's own cells or tissue. The company's most advanced project, IDO 8, is designed to restore the efficacy of hemophilia drugs in patients who have developed neutralizing antibodies. The company's second project, IDO T, is being developed to prevent kidney transplant rejection. In a third programme, IDO AID, Idogen is focused on the treatment of autoimmune diseases. The treatment for all indications is based on the patient's own

cells and is expected to have a favorable safety profile and long-lasting effect. The potential for a short-term treatment intervention to yield a long-term effect is a major advantage in health economics for both patients and divisions providing care. More information about Idogen is available via https://www.idogen.com